MedPath

DANA-FARBER CANCER INSTITUTE

🇺🇸United States
Ownership
-
Established
1947-01-01
Employees
-
Market Cap
-
Website
http://www.dana-farber.org/

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Phase 2
Recruiting
Conditions
Chordoma (Poorly Differentiated or De-differentiated)
Other SMARCA4-deficient Malignant Tumors (With PI Approval)
Atypical Teratoid/Rhabdoid Tumor
Other INI1 Negative Tumors (With PI Approval)
Rhabdoid Tumor of the Kidney
Malignant Rhabdoid Tumor
Epithelioid Sarcoma
Interventions
First Posted Date
2020-06-04
Last Posted Date
2023-11-28
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
45
Registration Number
NCT04416568
Locations
🇺🇸

Children's Healthcare of Atlanta-Egleston, Atlanta, Georgia, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

and more 5 locations

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Phase 2
Terminated
Conditions
Glioblastoma
Recurrent Glioblastoma
Interventions
Procedure: Surgery
Other: Placebo
First Posted Date
2020-05-28
Last Posted Date
2024-08-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
15
Registration Number
NCT04406272
Locations
🇺🇸

Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, Utah, United States

🇺🇸

University of California, Los Angeles (UCLA), Los Angeles, California, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

YES Study - Newly Diagnosed/Metastatic Intervention

Not Applicable
Recruiting
Conditions
Breast Cancer
Symptom, Behavioral
Interventions
Behavioral: YES portal
First Posted Date
2020-05-07
Last Posted Date
2024-05-14
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
400
Registration Number
NCT04379414
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Not Applicable
Recruiting
Conditions
Invasive Breast Cancer
Mantle Cell Lymphoma
Larynx Cancer
Bladder Cancer
Gastric Cancer
in Situ Breast Cancer
Interventions
Radiation: Viewray MRIdian® Linac
First Posted Date
2020-04-30
Last Posted Date
2024-08-27
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
70
Registration Number
NCT04368702
Locations
🇺🇸

Brigham & Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care

Not Applicable
Withdrawn
Conditions
Gynecologic Cancer
Cervical Cancer
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma
Uterine Cancer
Interventions
Behavioral: SIGNAL
First Posted Date
2020-04-29
Last Posted Date
2022-10-14
Lead Sponsor
Dana-Farber Cancer Institute
Registration Number
NCT04368130
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Step Into Support for Endurance and Strength (SISTERS)

Not Applicable
Completed
Conditions
Gynecologic Cancer
Interventions
Other: Fitbit
Other: Fitbit + Game + Support from a Teammate
First Posted Date
2020-04-21
Last Posted Date
2023-04-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
21
Registration Number
NCT04354454
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Northern Light Cancer Care, Brewer, Maine, United States

🇺🇸

Lifespan Comprehensive Cancer Center, Providence, Rhode Island, United States

Phase I Study of Marizomib + Panobinostat for Children With DIPG

Phase 1
Terminated
Conditions
Diffuse Intrinsic Pontine Glioma
Pediatric Brainstem Glioma
Pediatric Brainstem Gliosarcoma, Recurrent
Pediatric Cancer
Pediatric Brain Tumor
Diffuse Glioma
Interventions
First Posted Date
2020-04-10
Last Posted Date
2024-02-15
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
4
Registration Number
NCT04341311
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cemiplimab in AlloSCT/SOT Recipients With CSCC

Phase 1
Completed
Conditions
Advanced Cancer
Cutaneous Squamous Cell Carcinoma
Interventions
First Posted Date
2020-04-08
Last Posted Date
2025-04-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
12
Registration Number
NCT04339062
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

Not Applicable
Completed
Conditions
Metastatic Prostate Cancer
Ovarian Cancer
Pancreatic Cancer
Breast Cancer
Interventions
Behavioral: Standard Genetic Counseling
Behavioral: Educational Video
First Posted Date
2020-04-01
Last Posted Date
2024-01-19
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
269
Registration Number
NCT04330716
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute at St. Elizabeth's Medical Center, Brighton, Massachusetts, United States

🇺🇸

Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States

and more 3 locations

Intervention For AYAS With Cancer Risk Syndromes

Not Applicable
Recruiting
Conditions
Cancer Risk Syndrome
Interventions
Behavioral: AYA-RISE Adolescents and Young Adults Risk Information and Screening Education
Behavioral: Standard clinical visit for genetic counseling
First Posted Date
2020-03-27
Last Posted Date
2025-01-30
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
354
Registration Number
NCT04323774
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath